TOKYO – Locust Walk and Thomson Reuters are pleased to announce the winners of the top industry deals of the year in Japan, which were announced at “Celebrating Innovation 2015”, an evening to that brought together approximately 50 executives across the Japan biotech and pharmaceutical space.
The three categories that were featured were top in-licensing deals, top out-licensing deals and top M&A deals among Japanese biopharma, and each had a great selection of candidates to choose from. The winners of the annual Locust Walk Japan Deal of the Year Awards were selected by those that attended the event and they were as follows:
- Top In-Licensing Deal: Mitsubishi Tanabe Pharma in collaboration with Regeneron for Fasinumab
- Top Out-Licensing Deal: Mitsubishi Tanabe Pharma in collaboration with Biogen for MT-1303
- Top M&A Deal: Sosei’s $400M acquisition of Heptares Therapeutics
The event took place at the Tesla Showroom in Tokyo on December 16. To learn more about the Locust Walk Japan Deal of the Year Awards and Celebrating Innovation, please contact Locust Walk’s Steve Engen, SVP Japan Asia.
About Locust Walk
Locust Walk (www.locustwalk.com) helps build bio pharma companies through transformative transactions. We assist Emerging BioPharma on a variety of deal processes including global and regional licensing, mergers and acquisitions, financings and IPOs. We assist Growth BioPharma to search and acquire as well as divest assets. In 2015, Locust Walk established its Asia office in Tokyo, Japan to service both western and Japanese biopharma seeking to execute cross-border, transformative transactions.
Contact: Steve Engen, email@example.com